About Us

large-target

The Target Systemic Mastocytosis Committee

Blueprint Medicines organized and engaged the Target SM Committee, a group of physicians with expertise in systemic mastocytosis that represent a wide range of specialties. Educational resources were developed by Blueprint Medicines in collaboration with the Target SM Committee, and Blueprint Medicines provided funding to the committee for their time and expertise in developing this content.

Cem Akin MD, PHD

Allergist/Immunologist

mariana-castells-about-pgtmariana-castells-about-highlight

Mariana Castells MD, PHD

Allerigist/Immunologist

daniel-deangelo-about-pgdaniel-deangelo-about-highlight

Daniel Deangelo MD, PHD

Hematologist/Oncologist

Cem Akin MD, PHD

Allergist/Immunologist

Dr. Akin is currently a Professor of Medicine at the University of Michigan in the Division of Allergy and Clinical Immunology. His clinical research interests include clinical, molecular, and therapeutic aspects of mastocytosis; pathophysiology and treatment of anaphylaxis and mast cell activation; mast cell biology; tyrosine kinase inhibitors; and allergic diseases. Dr. Akin is internationally recognized for his work on mast cell disorders and anaphylaxis, and he is an active member of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Dr. Akin is an investigator for ongoing clinical trials with Blueprint Medicines.

mariana-castells-about-pgtmariana-castells-about-highlight

Mariana Castells MD, PHD

Allerigist/Immunologist

Professor Castells is currently a clinician, researcher, and teacher at Brigham and Women's Hospital and Dana Farber Cancer Institute. She is the Director of the Drug Hypersensitivity and Drug Desensitization Center, as well as the Director of the Mastocytosis Center, and has served as the Allergy and Immunology Training Program Director for 20 years. She is the Research Chair Director of the American Academy of Allergy, Asthma & Immunology (AAAAI) Foundation, serves on the Board of Directors for the American Board of Allergy and Immunology (ABAI) and the Council for the Collegium International Allerogologicum (CIA), and directs the annual International Drug Desensitization Meeting (DDIM) in Barcelona, Spain. Professor Castells’ clinical research interests include drug anaphylaxis and hypersensitivity and mast cell inhibitory mechanisms.

Prof. Castells is an investigator for ongoing clinical trials with Blueprint Medicines.

daniel-deangelo-about-pgdaniel-deangelo-about-highlight

Daniel Deangelo MD, PHD

Hematologist/Oncologist

Dr. DeAngelo is currently a Professor of Medicine at Harvard Medical School and the Chief of the Division of Leukemia at Dana-Farber Cancer Institute. Dr. DeAngelo’s clinical research focuses on optimizing therapy for adult leukemias, myelodysplastic syndromes, and myeloproliferative disorders. He serves on the Leukemia Core Committee for the Cancer and Leukemia Group B (CALGB) and is a principal and co-investigator on several ongoing clinical protocols. He has a particular interest in the treatment of young adults with leukemia, particularly acute lymphoblastic leukemia. Dr. DeAngelo is actively involved in a number of professional societies such as the American Society of Hematology and the American Society of Clinical Oncology. In addition, he serves as a member of the National Comprehensive Cancer Network (NCCN) Guidelines® committees for Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL).

Dr. DeAngelo is an investigator for ongoing clinical trials with Blueprint Medicines.

Dr. Akin is currently a Professor of Medicine at the University of Michigan in the Division of Allergy and Clinical Immunology. His clinical research interests include clinical, molecular, and therapeutic aspects of mastocytosis; pathophysiology and treatment of anaphylaxis and mast cell activation; mast cell biology; tyrosine kinase inhibitors; and allergic diseases. Dr. Akin is internationally recognized for his work on mast cell disorders and anaphylaxis, and he is an active member of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Dr. Akin is an investigator for ongoing clinical trials with Blueprint Medicines.

Professor Castells is currently a clinician, researcher, and teacher at Brigham and Women's Hospital and Dana Farber Cancer Institute. She is the Director of the Drug Hypersensitivity and Drug Desensitization Center, as well as the Director of the Mastocytosis Center, and has served as the Allergy and Immunology Training Program Director for 20 years. She is the Research Chair Director of the American Academy of Allergy, Asthma & Immunology (AAAAI) Foundation, serves on the Board of Directors for the American Board of Allergy and Immunology (ABAI) and the Council for the Collegium International Allerogologicum (CIA), and directs the annual International Drug Desensitization Meeting (DDIM) in Barcelona, Spain. Professor Castells’ clinical research interests include drug anaphylaxis and hypersensitivity and mast cell inhibitory mechanisms.

Prof. Castells is an investigator for ongoing clinical trials with Blueprint Medicines.

Dr. DeAngelo is currently a Professor of Medicine at Harvard Medical School and the Chief of the Division of Leukemia at Dana-Farber Cancer Institute. Dr. DeAngelo’s clinical research focuses on optimizing therapy for adult leukemias, myelodysplastic syndromes, and myeloproliferative disorders. He serves on the Leukemia Core Committee for the Cancer and Leukemia Group B (CALGB) and is a principal and co-investigator on several ongoing clinical protocols. He has a particular interest in the treatment of young adults with leukemia, particularly acute lymphoblastic leukemia. Dr. DeAngelo is actively involved in a number of professional societies such as the American Society of Hematology and the American Society of Clinical Oncology. In addition, he serves as a member of the National Comprehensive Cancer Network (NCCN) Guidelines® committees for Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL).

Dr. DeAngelo is an investigator for ongoing clinical trials with Blueprint Medicines.

tracy-george-about-highlight

Tracy George MD

Pathologist

matthew-giannetti-about-pgmatthew-giannetti-about-highlight

Matthew Giannetti MD

Allergist/Immunologist

tracy-george-about-highlight

Tracy George MD

Pathologist

Dr. George is currently a Professor of Pathology at the University of Utah. She is also the President and Chief Medical Officer at ARUP Laboratories. Dr. George serves as President of the International Society for Laboratory Hematology and on the editorial boards for ARUP Consult and the International Journal of Laboratory Hematology. Her research and interests include the pathology of mast cell disease, translational hematopathology, and laboratory hematology. She received a Lifetime Achievement Award from the College of American Pathologists in 2014.

Dr. George is an investigator for ongoing clinical trials with Blueprint Medicines.

matthew-giannetti-about-pgmatthew-giannetti-about-highlight

Matthew Giannetti MD

Allergist/Immunologist

Dr. Giannetti is currently an Instructor in Medicine at Harvard Medical School and a clinical faculty member in the Division of Rheumatology, Immunology and Allergy at Brigham and Women’s Hospital, where he is also associate director of the Mastocytosis Center of Excellence. He serves as an ad hoc reviewer for Annals of Allergy, Asthma & Immunology. Dr. Giannetti’s clinical interests include mastocytosis and related mast-cell activation disorders, and he is involved in several translational research projects focused on understanding abnormal mast cell biology in patients with mastocytosis.

Dr. Giannetti is an investigator for ongoing clinical trials with Blueprint Medicines.

Dr. George is currently a Professor of Pathology at the University of Utah. She is also the President and Chief Medical Officer at ARUP Laboratories. Dr. George serves as President of the International Society for Laboratory Hematology and on the editorial boards for ARUP Consult and the International Journal of Laboratory Hematology. Her research and interests include the pathology of mast cell disease, translational hematopathology, and laboratory hematology. She received a Lifetime Achievement Award from the College of American Pathologists in 2014.

Dr. George is an investigator for ongoing clinical trials with Blueprint Medicines.

Dr. Giannetti is currently an Instructor in Medicine at Harvard Medical School and a clinical faculty member in the Division of Rheumatology, Immunology and Allergy at Brigham and Women’s Hospital, where he is also associate director of the Mastocytosis Center of Excellence. He serves as an ad hoc reviewer for Annals of Allergy, Asthma & Immunology. Dr. Giannetti’s clinical interests include mastocytosis and related mast-cell activation disorders, and he is involved in several translational research projects focused on understanding abnormal mast cell biology in patients with mastocytosis.

Dr. Giannetti is an investigator for ongoing clinical trials with Blueprint Medicines.

Blueprint Medicines and associated logos are trademarks of Blueprint Medicines Corporation.
© 2021 Blueprint Medicines Corporation.
07/2021 USBP-PRSM-20.001.2